Want to see ADGM full AI Analyst Report?
ADGM Stock Chart & Stats
$0.48
>-$0.01(-0.08%)
At close: 4:00 PM EDT
$0.48
>-$0.01(-0.08%)
Day’s Range― - ―
52-Week Range$0.36 - $2.58
Previous Close$0.47
Volume28.41K
Average Volume (3M)152.12K
Market Cap
$8.40M
Enterprise Value$36.72
Total Cash (Recent Filing)$12.91M
Total Debt (Recent Filing)$24.09M
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Aug 19, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside629.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.18
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
PMA Submission For Breakthrough VCLAS VT Ablation SystemA submitted PMA for a Breakthrough-designated, purpose-built VT ablation system backed by pivotal IDE data creates a durable path to commercial market access in a large ($5.8B) VT ablation market. Approval would transform a pre-revenue device company into a procedure-driven revenue generator with durable clinical differentiation backed by trial outcomes.
Clinical Progress: First Patient Treated Under FDA Expanded AccessTreatment of the first Expanded Access patient at a leading EP center demonstrates early real-world adoption, physician engagement, and operational execution of clinical programs. This durable progress supports post-approval uptake, data collection, and clinician familiarity, which are critical for sustained commercial adoption if regulatory approval follows.
Shareholder Support And Governance ContinuityStrong shareholder approval and auditor ratification indicate governance stability and investor confidence in oversight and financial reporting. Durable governance quality reduces execution and disclosure risk, improving credibility with partners, regulators, and capital providers during commercialization and additional financing needs.
Bears Say
Minimal Revenue And Persistent Cash BurnThe company lacks meaningful product revenue and consistently burns cash, demonstrating it cannot self-fund operations or commercialization. Persistent negative operating and free cash flow forces reliance on external capital, which can dilute shareholders or increase cost of capital and lengthen timelines for achieving sustainable margins.
Rising Leverage And Constrained Balance Sheet FlexibilityRapidly increasing debt-to-equity to ~4.21 materially raises fixed obligations and refinancing risk. With limited revenue and ongoing losses, higher leverage constrains strategic optionality, elevates insolvency risk in stress scenarios, and increases cost of incremental funding needed for commercialization and regulatory milestones.
Nasdaq Minimum Bid Price Noncompliance And Listing RiskFormal noncompliance with Nasdaq listing standards creates a structural governance and capital-access risk. Potential delisting or a forced reverse split can reduce liquidity, deter institutional participation, and complicate future equity raises needed to fund operations and scale commercialization, weakening long-term financing flexibility.
Adagio Medical Holdings News
ADGM FAQ
What was Adagio Medical Holdings’s price range in the past 12 months?
Adagio Medical Holdings lowest stock price was $0.36 and its highest was $2.58 in the past 12 months.
What is Adagio Medical Holdings’s market cap?
Adagio Medical Holdings’s market cap is $8.40M.
When is Adagio Medical Holdings’s upcoming earnings report date?
Adagio Medical Holdings’s upcoming earnings report date is Aug 19, 2026 which is in 15 days.
How were Adagio Medical Holdings’s earnings last quarter?
Adagio Medical Holdings released its earnings results on May 12, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.02.
Is Adagio Medical Holdings overvalued?
According to Wall Street analysts Adagio Medical Holdings’s price is currently Undervalued.
Does Adagio Medical Holdings pay dividends?
Adagio Medical Holdings does not currently pay dividends.
What is Adagio Medical Holdings’s EPS estimate?
Adagio Medical Holdings’s EPS estimate is -0.27.
How many shares outstanding does Adagio Medical Holdings have?
Adagio Medical Holdings has 22,210,459 shares outstanding.
What happened to Adagio Medical Holdings’s price movement after its last earnings report?
Adagio Medical Holdings reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -1.915%.
Which hedge fund is a major shareholder of Adagio Medical Holdings?
Currently, no hedge funds are holding shares in ADGM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adagio Medical Holdings
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
ADGM Stock 12 Month Forecast
Average Price Target
$3.50
▲(629.17% Upside)
Technical Analysis
Ownership Overview
45.47% Insiders
0.47% Mutual Funds
<0.01% Other Institutional Investors
53.56% Public Companies and
Individual Investors